The goal of this observational study is to deepen our understanding of long COVID by determining the prevalence of the main complications and medium- to long-term sequelae of COVID-19 in Navarre.
Sociodemographic variables such as age, sex, ethnicity, smoking history, and comorbidities will be collected, as well as clinical and disease management variables such as persistent COVID-19 symptoms at 3 months, all with the aim of characterizing patients with long COVID.
All patient data will be collected in a single visit.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* History of confirmed SARS-CoV-2 infection
* Presentation of symptoms that have persisted for more than 3 months after SARS-CoV-2 infection
* The patient reports any of the symptoms listed in the clinical assessment questionnaire or checklist.
Exclusion Criteria:
* The symptom(s) referred to already existed prior to acute SARS-CoV-2 infection.
Primary outcome measure(s)
Describe the demographic, clinical and analytical characteristics of patients with persistent COVID in our setting. — Basal visit The following sociodemographic variables: age, gender, ethnicity, smoking history, and comorbidities, and analytical variables, will be collected.
Establish the prevalence of different symptoms, complications and/or medium- to long-term sequelae of COVID-19 in Navarre. — Basal visit 6\) Diagnosis of:
* Thromboembolic disease (deep vein thrombosis and/or pulmonary embolism at discharge and/or pulmonary thromboembolism).
* Acute cerebrovascular accident (embolic and/or atherothrombotic: referred to as stroke/ACVA/TIA/cerebral infarction) during admission for COVID-19. Establish assessment criteria by Internal Medicine and/or Neurology.
* Peripheral arterial ischaemic event during admission for COVID-19
* Acute complication of pre-existing coronary artery disease and/or acute coronary event (acute coronary syndrome or ACS).
* suspicion and/or diagnosis of myopericarditis during admission.
* criteria for acute hepatitis (GOT and/or GPT \>5 times normal range (\>200 during admission) and/or liver dysfunction (Br \>3 mg/dl).
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.